Moderna's stock price plummeted 20% in early trading! Sales of two flagship products were disappointing, leading to a significant cut in the annual revenue forecast.

① The American vaccine manufacturer Moderna expects revenue for 2025 to be between 1.5 billion and 2.5 billion USD due to a slowdown in demand for its two main products, which is significantly lower than the previously expected 2.5 billion to 3.5 billion USD; ② Moderna's stock price fell 20% due to the lowered revenue expectations, with its CEO stating that the adjustment reflects increased competition in the COVID-19 vaccine market, delayed infrastructure development, and a decline in vaccination rates.

cls.cnJan 13 23:01

A Mixed Bag of Factors Influencing Moderna's Stock This Month

Yahoo Finance7minutes ago

The Top and Bottom Contributors to S&P 500's Q4 EPS Growth

Seeking Alpha7minutes ago

Unusual Options Activity: ACI, MRNA and Others Attract Market Bets, ACI V/OI Ratio Reaches 357.1

EST Jan 13th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.

Futu News24minutes ago

Moderna Plunges, Retail Guidance, Bitcoin Falls: Market Minute

Yahoo Finance27minutes ago

Moderna's Stock Crashes 22%--Pandemic Hero Now Fighting for Survival

Yahoo Finance32minutes ago